



Republic of Serbia  
**COMMISSION FOR PROTECTION  
OF COMPETITION**

25/IV Savska St., Belgrade  
Number: 6/0-02-164/2019-12  
Date: February 11, 2019

Published text contains protected data.  
Protected data are presented with symbol [...] or in the range that the Commission finds to be an appropriate manner of protection.

Pursuant to Article 37(2) and Article 65(5) of the Law on Protection of Competition (Official Gazette of the RS 51/09 and 95/13), and Article 2(1/6) of the Tariff on the level of compensations for activities within the competence of the Commission for Protection of Competition (Official Gazette of the RS 49/11), deciding under the notification of concentration entered under number 6/0-02-164/2019-1 of January 3, 2019, submitted by company GlaxoSmithKline plc., with registered seat at the address 980 Great West Road, Brentford, TW8 9GS, United Kingdom, via procurator holder, attorney at law Srđana Petronijević from the Law Office “Moravčević, Vojnović i partneri”, 15 Dobračina St., Belgrade, on February 11, 2019, the President of the Commission for Protection of Competition enacts the following

### **DECISION**

**I** Concentration of undertakings in summary procedure **IS APPROVED** created by acquisition of individual control on the part of company GlaxoSmithKline plc., with registered seat at the address 980 Great West Road, Brentford, TW8 9GS, United Kingdom, company number 03888792, over business operations of company Pfizer Inc., with registered seat at the address 235 East 42nd Street, New York, NY 10017, United States of America, company number 1-3619, in the field of consumer health protection, pursuant to the Stock and Asset Purchase Agreement.

**II IT IS ESTABLISHED** that the Party, company GlaxoSmithKline plc., has made payment in full in the amount of RSD 2,960,165.00 (in words: two million, nine hundred sixty thousand, one hundred sixty-five dinars) into the account of the Commission for Protection of Competition, which represents a dinar-currency equivalent value of the fee as compensation for issuing decision on the approval of concentration in summary procedure, calculated at the middle exchange rate of the National Bank of Serbia on the day of payment.